Sumitomo Pharma Co., Ltd.
Notice of Differences Between Consolidated Earnings Guidance and Actual Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 and Revision to Full-Year Consolidated Earnings Guidance
Second-quarter results exceeded the prior guidance, prompting an upward revision to the full-year forecast. Revenue is revised to 565,000 million yen, core operating profit to 105,000 million yen, operating profit to 104,000 million yen, and net income attributable to owners of the parent to 94,000 million yen. Foreign exchange assumptions were also revised.
Key Figures
- Revenue: 2,665,000 million yen (interim results)
- Full-year Revenue: 5,650,000 million yen (revised)
- Full-year Core Operating Profit: 1,050,000 million yen (revised)
AI要約
Summary of Forecast Revisions
Sumitomo Pharma Co., Ltd. has upwardly revised its full-year consolidated earnings guidance following second-quarter results that exceeded the previously announced guidance. Revenue for the interim period increased to 266,500 million yen, core operating profit to 42,100 million yen, operating profit to 42,300 million yen, and interim net income attributable to owners of the parent to 38,200 million yen. Considering foreign exchange effects, the full-year exchange rate assumption has been revised to 1 USD = 157 yen.
Outlook and Impact for Investors
As a result of this revision, sales growth is expected to proceed as assumed, which may have a positive effect on shareholder returns and investment decisions. Investors should monitor foreign exchange volatility, new drug and therapeutic sales trends, and SG&A expense developments, as these factors could materially affect future performance.
Sumitomo Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
